Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COGNITION-GUIDE: Genomics-guided post-neoadjuvant therapy in early breast cancer
NCT05332561Phase 2Recruiting
- Sponsor
- German Cancer Research Center
- Start
- Jun 2023
- Primary completion
- Mar 2030
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab, inavolisib, ipatasertib, olaparib, sacituzumab govitecan and 2 more in breast cancer (7 arms), sponsored by German Cancer Research Center. Primary endpoint: Invasive Disease-Free Survival at 4 years. Started Jun 2023; status: recruiting.
02
Drugs
atezolizumabinavolisibipatasertibolaparibsacituzumab govitecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05332561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05332561.